Japan’s Nikkei plunged 2.97%, tracking Wall Street’s technology sell-off as rising global bond yields and renewed Middle East uncertainty dampened risk appetite. Semiconductor stocks led declines, with Kioxia and Furukawa Electric falling over 10%. SoftBank also dropped sharply, while Mercari, Shiseido and Otsuka Holdings gained despite the broad market decline.
On Wednesday morning, Indian stock markets faced further setbacks as both the Sensex and Nifty indices continued their downward trend, marking an ongoing losing streak. The broader market indices echoed this sentiment, showing substantial selling pressure. Notably, shares of Bajaj Finserv and Bajaj Finance led the decline on the Sensex, while IT stocks such as HCL Tech and Infosys managed to defy the overall trend by recording gains.
BSE shares have experienced a significant downturn this month following the launch of a new closing auction session. Since this change on August third, trading volumes and options activity have considerably dropped, raising concerns among analysts who have downgraded their outlook on the stock. The exchange is grappling with new funding rules and possible fee changes, but some analysts remain optimistic about a turnover rebound by October.
US housing activity weakened sharply in July, with single-family homebuilding hitting a more than three-and-a-half-year low as high mortgage rates and economic uncertainty weighed on demand. In contrast, factory output rose, supported by strong AI-related investment and demand for high-tech equipment and semiconductor production.
Persistently high US Treasury auction yields are raising the cost of refinancing government debt and funding future deficits as investors demand greater compensation to absorb rising borrowing needs. Recent 10-year and 30-year auctions saw yields hit multi-year highs, though resilient demand suggests there is no broad buyer strike. The key concern for Washington is the growing cost of servicing a large and persistent fiscal deficit.
Four Nifty500 stocks surged over 5% on August 18, triggering StockEdge’s White Marubozu bullish scanner, signalling strong buying momentum and sustained investor interest across these stocks.
The impressive earnings reported in the first quarter have led brokerages to unveil fresh stock-picking avenues. Investors are encouraged to seek out firms showcasing strong earnings and solid financial fundamentals. A collective effort from various brokerages has resulted in the identification of fifty prime stock options, covering diverse industries such as banking, automotive, and defense. The market is now pivoting towards an earnings-led cycle with an emphasis on quality companies.
Symbiotec Pharmalab will launch its ₹1,757-crore IPO from August 24–27, 2026, with a price band of ₹938–988 per share. The minimum bid is 15 shares, requiring an investment of ₹14,820 at the upper price band. The IPO is expected to list on BSE and NSE on September 1, with allotment likely on August 28. At the upper band, the issue values the company at a steep 52 times FY26 diluted EPS.
The three-day IPO will remain open until August 21, 2026, with the company offering shares in a price band of Rs 152–160 apiece.
Warning! Information Posting in this website is only for educational purpose. We are not responsible for losses incurred in Trading based on this information.